GPT and chronic myelogenous leukemia, BCR-ABL1 positive: The authors showed, nevertheless, a specific sensitivity of resistant CML cell lines when combined, validating the strategy of targeting the ALT-NHEJ pathway as an interesting therapeutic target, not only in CML but also in other cancers relying on the same mechanisms.